Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06957821 · ClinicalTrials.gov registry record · Early Phase 1
Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
NCT06957821: Clinical Trial Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT06957821 is a Early Phase 1 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06957821, a Early Phase 1 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective care - and may help prevent heart attacks. Right now, there's no imaging technology available to clearly see inflammation inside the coronary arteries. The investigators hope to learn how an imaging drug; called LUMISIGHT (Pegulicianine) can help detect inflammation in blood vessels compared with saline. If the investigators find out that LUMISIGHT is active in humans, the investigators might be able to use it for detecting plaque risk in the future.
Interventions
- OTHER Placebo
- DRUG Pegulicianine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06957821
The ClinicalTrials.gov registry entry for NCT06957821 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06957821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06957821 about?
NCT06957821 is a clinical study titled "Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques". Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective ...
What is the current status of trial NCT06957821?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2026-06. Estimated completion is 2029-12.
What interventions are being tested in trial NCT06957821?
The interventions under investigation include: Placebo (OTHER), Pegulicianine (DRUG).
Who is sponsoring clinical trial NCT06957821?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.